Prescient Therapeutics Ltd at Small Caps to discuss the company's plans for its innovative cancer therapies PTX-100 and PTX-200. Transcript
Welcome to Small Caps, ladies and gentlemen. My name is Kerry Stevenson. Today I'm speaking with Steven Yatomi-Clarke. He is the Managing Director and CEO of Prescient Therapeutics, which is a really interesting company. The ASX code is PTX. They have four blue chip oncology assets, and you'll see them behind Steven's head at the movement, which makes it really easy PTX-100, PTX- 200, OmniCAR and CellPryme. So thanks for making my job easy Stephen, and welcome back to Small Caps.
Thank you so much, Kerry. Delight to be speaking with you again.
Questions & Answers
Well, it's been a year, Stephen. So let's start because I can't believe it's let's not leave it that long next time because there's been a lot of development with Prescient. So first up, can you give us a brief overview of those four assets that you have got?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
